Vedere Bio II
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Vedere Bio II researched gene therapies to restore or preserve vision in people with retinal degeneration.
02 / Vedere Bio II FAILURE REASONS
Failure reasons
Its leaders established demanding efficacy targets for preclinical studies. The broader test results did not meet that threshold, so they decided to discontinue the research and wind down the company. Early promising findings were not enough to justify continuing development.
03 / EVENT HISTORY
Events in the structured record
- New company launched
Vedere Bio II launched in May with financing to pursue new ocular gene therapies, separate from the earlier Vedere company acquired by Novartis.
- Preclinical findings presented
The team presented early research data while continuing preclinical development.
- Research discontinued and wind-down
At the end of March, leaders announced discontinuation after evaluating efficacy studies; April reports confirmed the wind-down.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Vision-restoration therapies underwent preclinical testing
- 02
Results failed the company’s efficacy threshold
- 03
Leaders discontinued research
- 04
Company wound down